Tilbake til: Farma og medisin
Innlegg av: Gullsteinvik (12.10.17 07:09 ), lest 10846 ganger
Ticker: TRVX
Endret: 12.10.17 07:15

TRVX - MELDING - 100% of patients (13/13)

Oslo, Norway, 11 October 2017: Targovax ASA ("Targovax" or "the Company"; OSE:
TRVX), a clinical stage company focused on developing immuno-oncology therapies
to target solid tumors, today announces one-year data on survival rate, immune
activation and safety in the modified cohort of the TG01 trial in resected
pancreatic cancer patients.

The trial is an open label, phase I/II trial of TG01/GM-CSF in combination with
gemcitabine as adjuvant therapy for treating patients with resected
adenocarcinoma of the pancreas. The trial consists of two cohorts: the main
cohort of 19 patients and a second, modified cohort of 13 patients. The purpose
of the modified cohort is to build on the positive findings from the main cohort
in order to further optimize the TG01 treatment regimen and safety profile of
the combination therapy. Although manageable, some allergic reactions were seen
in patients in the main cohort when treating with TG01 and gemcitabine in
parallel. Hence, the modified cohort received fewer TG01 injections overall than
the main cohort, administered non-concomitantly with gemcitabine.

The modified cohort started recruitment in 2015 (link to PR), and the last
patient enrolled has now been in the trial for one year. The one-year survival
rate and safety data in the modified cohort showed that:
* 100% of patients (13/13) were alive one year after surgery
* TG01/GM-CSF generated an immune response in 85% of patients (11/13)
* No serious adverse events related to allergic reactions have been reported

Magnus Jäderberg MD, Chief Medical Officer of Targovax, said, "We are delighted
that we maintain a strong immune response and one-year survival rate with the
reduced dosing regimen, essentially equivalent to and consistent with the
previously reported data from the main cohort. This further strengthens the
safety profile of TG01, and adds valuable understanding that will help us
optimize the dosing regimen in resected pancreatic cancer patients, a condition
which is notoriously difficult to treat. We look forward to see the two-year
survival data for the modified cohort next year."

The data from the main cohort was presented here.




For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Jan Petter Stiff - Crux Advisers (Norway)
Phone: +47 995 13 891
Email: stiff@crux.no

Julia Phillips/Simon Conway - FTI Consulting (International)
Phone: +44 20 3727 1000
Email: Targovax@fticonsulting.com